Podcast

What Patients With Blood Cancers Need to Know About COVID-19, Booster Shots and More

Author(s):

Jamie Cesanek

An expert from the Leukemia & Lymphoma Society breaks down the effectiveness of the COVID-19 vaccine in patients with blood cancers on this episode of the “Cancer Horizons” podcast.

With recent research demonstrating that antibodies were not detected in some patients with B-cell blood cancers after receiving two doses of the COVID-19 vaccine, many people have questions. Will a third dose help these patients? Should they bother with the vaccine? How do their current cancer treatments impact the vaccine’s effectiveness?

Dr. Larry Saltzman, the executive research director at the Leukemia & Lymphoma Society, answered these questions and more in this episode of the “Cancer Horizons” podcast.

“So there's two swings of the pendulum, those who will respond in a global, very good way – not to worry, essentially, and those (who) will not respond due to the treatments that they're on,” Saltzman said.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Image of a woman with a brown hair tied into a bun.
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Related Content
FDA approves Ryoncil for children with GVHD.
December 18th 2024

Ryoncil Receives FDA Approval for Children With GVHD

Darlene Dobkowski, MA
This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of blood test.
December 10th 2024

Venclexta Plus Mavenclad Boosts Response Rates in AML, MDS

Ariana Pelosci
The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Illustration of blood cells.
December 8th 2024

Scemblix May Outperform Standard Treatments for Chronic Myeloid Leukemia

Megan Hollasch
Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in patients with chronic myeloid leukemia.
Image of blood test.
December 8th 2024

Tecartus Shows Similar Efficacy Across Age Groups in Leukemia

Kyle Doherty
Tecartus demonstrated similar effectiveness across age groups of patients with relapsed or refractory B-cell acute lymphoblastic leukemia.